# Vaxcyte Posts $1.99 Q3 GAAP Loss Per Share, 15 Cents Better Than Estimate

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/49636
Published: 2026-11-05T23:41:54.000Z
Updated: 2026-11-05T23:41:54.000Z
Section: Business

> Cash, cash equivalents and investments totaled $2,264.4 million on Sept. 30, down from $2,442.6 million at year-end 2025.

In results announced Nov. 4, Vaxcyte posted a third-quarter GAAP loss of $1.99 per share, 15 cents better than the estimate, while cash, cash equivalents and investments totaled $2,264.4 million at Sept. 30.

The combined balance was $2,442.6 million at Dec. 31, 2025.